3401 N. Central Avenue Chicago, IL 60634




What is this study investigating:

The purpose of this study is to research the safety and efficacy of Spravato® used as a monotherapy treatment for treatment-resistant depression.

What Is Spravato® (Esketamine)? Spravato® was FDA-Approved in 2019 to be used in conjunction with an oral antidepressant to target depressive symptoms that traditional antidepressants have failed to address. This is the only medication FDA-approved for treatment-resistant depression. Spravato® is dosed intranasally on a weekly to biweekly basis. This medication is rapid-acting compared to many antidepressants on the market.

Overview: This is a 4-month long clinical trial that entails weekly in-person clinic visits. Spravato® is not a medication you are allowed to take home with you, and is required to be dosed in office under clinical supervision. The first 4-weeks of the treatment phase are placebo controlled, and the remainder of the 3-months of the study are open label (no placebo control, guaranteed medication).

You May Qualify If:
–        You are 18 or older
–        You have tried and failed on at least TWO (2) antidepressant medications
–        You are currently experiencing symptoms of depression
–        You may be eligible regardless of whether or not you are currently treating your depression
–        Please Note: You will be required to show verification of trials on at least two (2) antidepressant medications

Qualified candidates may earn up to $75 per visit. Free transportation assistance provided to those who enroll.

Contact Us